Biotech of the Week: Opko Health Inc.
Opko Health competes with Laboratory Corporation of America and Quest Diagnostics on the diagnostics side and is partnered with Tesaro on the therapeutics side.
Should You Buy Tesaro After Its Earnings Miss?
Tesaro just missed earnings estimates by $0.37 per share for its first quarter. Is this stock a bad news buy?
Is Biotech in a Bubble? The Bear Case Explained
Biotech IPOs provide some powerful indications...
Why 2014 May Be a Big Year for Opko Health, Inc.
Opko's (OPK) has a number of catalysts this year that could have a big impact on its biggest investor, Philip Frost; including a Tesaro's (TSRO) potential FDA filing for Rolapitant.